J&J's Schizophrenia Drug Wins FDA Priority Review

The U.S. FDA has granted priority review to J&J's Janssen Pharmaceuticals' new drug application for antipsychotic Invega Trinza.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news